What are the side effects of Petrelintide?
The most commonly reported Petrelintide side effects are mild nausea, reduced appetite, constipation. Most are mild and tend to be dose dependent. It is generally avoided with mTC / MEN-2 history. Human clinical evidence for Petrelintide is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported Petrelintide side effects
- Mild nausea
- Reduced appetite
- Constipation
- Generally cleaner profile than GLP-1 monotherapy
Who should avoid it
- MTC / MEN-2 history
- Pancreatitis history
- Pregnancy / nursing
Bloodwork worth tracking
- Lipid panel
- A1C if metabolic context
References
- Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity — Zealand Pharma (press release via GlobeNewswire), March 5, 2026
- Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity — Roche (press release), March 5, 2026
- A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) — ClinicalTrials.gov, NCT06926842 (Sponsor: Zealand Pharma)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Petrelintide
Last updated 2026-06-06.